AstraZeneca PLC (NYSE: AZN) observed a decline of -1.89% on Tuesday trading period with closing price of $47.2. The company’s last traded volume of 3638293 shares vs to an average volume of 3257.32K shares. The stock as of last trading session moved at 33.71% from its 52-week low and was trading at -4.09% to its 52-week high.
Antengene Corporation recently reported that it has entered into a licensing contract with AstraZeneca (LSE/STO/ AZN) under which Antengene has been granted the exclusive global rights to further develop and commercialize AZD0364. Antengene Corporation is a China-and-U.S. based clinical-stage bio-pharmaceutical company focused on discovery and development of novel drugs for treatment of oncology. AstraZeneca is a global, science-led, innovative bio-pharmaceutical company. AZD0364 is a potent and selective small molecule extracellular signal–regulated kinases 1 and 2 (ERK1/2) inhibitor with an open U.S. investigation-al new drug (IND) application.
ERK is a key component of the Ras-Raf-MEK-ERK (RAS/MAPK) pathway, which is frequently altered in cancer and promotes tumour cell growth and survival. AZD0364 is a potent and selective inhibitor of ERK1/2 discovered by AstraZeneca. Any existing contract regarding the licensing of AZD0364 has been nullified in advance of this contract between Antengene and AstraZeneca.
Jay Mei, Founder and Chief Executive Officer of Antengene Corporation commented, “We are delighted to have the prospects to work with AstraZeneca. ERK/RAS/MAPK is a key pathway excessively activated in cancers. AZD0364 is a planned fit to our pipeline and pre-clinical studies demonstrated promising synergistic effects of AZD0364 in combination with other pipeline assets of Antengene targeting critical pathways in cancer treatment. We look forward to a close alliance with AstraZeneca to bring more novel therapies to patients with unmet medical needs.”
Analyst recommendation for this stock stands at 1.6. The volatility in the previous week has experienced by 1.58% and observed of 1.37% in the previous month. 18.80% ownership is held by institutional investors while insiders hold ownership of 0.50%. In the trailing 12 months period, return on assets ratio of the Company was 3.40% and return on equity ratio was 16.90% while its return on investment ratio was 10.90%. The P/E ratio was recorded at 58.63. Looking about the past performance history, the company lost at -0.82% in past week and climbed with 8.66% in one month. During the past three-month period the stock surged of 7.47% and increased at 23.24% in past six month. During the twelve month it rose at 24.70% and year to date performance of 24.28%.